Compare SOTK & BYSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SOTK | BYSI |
|---|---|---|
| Founded | 1975 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 61.6M | 79.0M |
| IPO Year | 1987 | 2017 |
| Metric | SOTK | BYSI |
|---|---|---|
| Price | $3.72 | $2.23 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 13.0K | ★ 639.6K |
| Earning Date | 01-12-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 6.63 | N/A |
| EPS | ★ 0.10 | N/A |
| Revenue | ★ $20,607,030.00 | N/A |
| Revenue This Year | $2.67 | N/A |
| Revenue Next Year | $8.20 | N/A |
| P/E Ratio | $38.03 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.23 | $0.98 |
| 52 Week High | $6.05 | $3.44 |
| Indicator | SOTK | BYSI |
|---|---|---|
| Relative Strength Index (RSI) | 36.12 | 55.99 |
| Support Level | $3.52 | $1.89 |
| Resistance Level | $3.95 | $2.16 |
| Average True Range (ATR) | 0.21 | 0.19 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 36.76 | 47.54 |
Sono-Tek Corp design and manufacture of ultrasonic coating systems for applying precise, thin film coatings to add functional properties, protect or strengthen surfaces on parts and components for the microelectronics/electronics, alternative energy, medical, industrial and emerging research & development/other markets. The company design and manufacture custom-engineered ultrasonic coating systems incorporating its patented technology, in combination with strong applications engineering knowledge, to assist its customers in achieving their desired coating solutions.
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It operates in Plinabulin pipeline segment.